Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor

被引：469

作者：

Yoka H. Kusumanto

Wendy A. Dam

Geke A.P. Hospers

Coby Meijer

Nanno H. Mulder

机构：

[1] Department of Medical Oncology, University Hospital Groningen, Groningen

[2] Department of Medical Oncology, University Hospital Groningen, 9713 GZ Groningen

来源：

Angiogenesis | 2003年 / 6卷 / 4期

关键词：

Assay; Circulating vascular endothelial growth factor; Neutrophils; Peripheral blood cells; Vascular endothelial growth factor;

D O I：

10.1023/B:AGEN.0000029415.62384.ba

中图分类号：

学科分类号：

摘要：

The measurement of circulating vascular endothelial growth factor (VEGF) levels as a prognostic factor will gain increasing relevance in the diagnosis and evaluation of treatment in cancer patients. Angiogenesis is an absolute requirement in tumour growth and metastatic disease. In the present study data are presented which indicate that circulating VEGF mainly resides in peripheral blood cells. In 15 healthy volunteers we demonstrated that approximately 34% of the circulating VEGF resides in platelets and approximately 11% in patients with cancer (n = 4). An important part namely 58% in healthy volunteers and 69% in patients with cancer of the total circulating VEGF is contained in granulocytes, particular in the neutrophils, as confirmed by fluorescence-activated cell sorting (FACS). Also an increased VEGF level per granulocyte is found in patients with cancer (77 μg VEGF/1) compared with the healthy volunteers (164 μg VEGF/1). In contrast only 2% was present in plasma. The biological significance of platelet- or granulocyte-derived VEGF is not yet known. Liberation of VEGF from these compartments could well be of importance for tumour angiogenesis. Therefore, future studies on the clinical value of circulating VEGF as a prognostic factor in cancer patients should include measurements of VEGF in peripheral blood cells.

引用

页码：283 / 287

页数：4

共 21 条

[1]

Senger D.R., Galli S.J., Dvorak A.M., Et al., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid, Science, 219, pp. 983-985, (1983)

[2]

Ferrara N., Vascular endothelial growth factor, Eur J Cancer, 32 A, pp. 2413-2422, (1996)

[3]

Adams J., Carder P.J., Downey S., Et al., Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen, Cancer Res, 60, pp. 2898-2905, (2000)

[4]

Oehler M.K., Caffier H., Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer, Anticancer Res, 20, pp. 5109-5112, (2000)

[5]

Kumar H., Heer K., Lee P.W., Et al., Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer, Clin Cancer Res, 4, pp. 1279-1285, (1998)

[6]

Ugurel S., Rappl G., Tilgen W., Reinhold U., Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival, J Clin Oncol, 19, pp. 577-583, (2001)

[7]

Matsuyama W., Hashiguchi T., Mizoguchi A., Et al., Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer, Chest, 118, pp. 948-951, (2000)

[8]

Verheul H.M., Hoekman K., Luykx-de Bakker S., Et al., Platelet: Transporter of vascular endothelial growth factor, Clin Cancer Res, 3, pp. 2187-2190, (1997)

[9]

Webb N.J., Bottomley M.J., Watson C.J., Brenchley P.E., Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: Implications for measurement of circulating VEGF levels in clinical disease, Clin Sci, 94, pp. 395-404, (1998)

[10]

Banks R.E., Forbes M.A., Kinsey S.E., Et al., Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology, Br J Cancer, 77, pp. 956-964, (1998)

← 1 2 3 →